Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Amortization of Deferred Charges: 2009-2023

Historic Amortization of Deferred Charges for Fortress Biotech (FBIO) over the last 7 years, with Dec 2023 value amounting to $353,000.

  • Fortress Biotech's Amortization of Deferred Charges fell 11.94% to $177,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $504,000, marking a year-over-year decrease of 35.71%. This contributed to the annual value of $353,000 for FY2023, which is 54.16% down from last year.
  • Fortress Biotech's Amortization of Deferred Charges amounted to $353,000 in FY2023, which was down 54.16% from $770,000 recorded in FY2022.
  • Fortress Biotech's Amortization of Deferred Charges' 5-year high stood at $781,000 during FY2021, with a 5-year trough of $353,000 in FY2023.
  • In the last 3 years, Fortress Biotech's Amortization of Deferred Charges had a median value of $770,000 in 2022 and averaged $634,667.
  • Per our database at Business Quant, Fortress Biotech's Amortization of Deferred Charges increased by 12.05% in 2021 and then crashed by 54.16% in 2023.
  • Fortress Biotech's Amortization of Deferred Charges (Yearly) stood at $697,000 in 2020, then grew by 12.05% to $781,000 in 2021, then declined by 1.41% to $770,000 in 2022, then plummeted by 54.16% to $353,000 in 2023.